Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC).


Journal

Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004

Informations de publication

Date de publication:
15 Mar 2021
Historique:
received: 21 01 2021
accepted: 19 02 2021
revised: 04 02 2021
entrez: 16 3 2021
pubmed: 17 3 2021
medline: 17 3 2021
Statut: epublish

Résumé

Non-small cell lung cancer (NSCLC) has limited treatment options. Expression of the RNA-binding protein (RBP) Musashi-2 (MSI2) is elevated in a subset of non-small cell lung cancer (NSCLC) tumors upon progression, and drives NSCLC metastasis. We evaluated the mechanism of MSI2 action in NSCLC to gain therapeutically useful insights. Reverse phase protein array (RPPA) analysis of MSI2-depleted versus control Kras

Identifiants

pubmed: 33723247
doi: 10.1038/s41389-021-00317-y
pii: 10.1038/s41389-021-00317-y
pmc: PMC7961039
doi:

Types de publication

Journal Article

Langues

eng

Pagination

29

Subventions

Organisme : NCI NIH HHS
ID : R03 CA216173
Pays : United States
Organisme : NIDCR NIH HHS
ID : P50 DE030707
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218802
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA223394
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221675
Pays : United States

Références

Ann Transl Med. 2017 Nov;5(21):424
pubmed: 29201876
J Biol Chem. 2014 May 16;289(20):14239-51
pubmed: 24644291
J Clin Invest. 2015 Mar 2;125(3):1286-98
pubmed: 25664853
Nature. 2012 May 06;486(7401):126-9
pubmed: 22678294
Mol Cell Proteomics. 2014 Jul;13(7):1625-43
pubmed: 24777629
Nat Commun. 2020 Apr 24;11(1):2026
pubmed: 32332729
J Exp Med. 2014 Jan 13;211(1):71-87
pubmed: 24395885
Nat Commun. 2019 Jun 19;10(1):2691
pubmed: 31217428
Blood. 2009 Jan 1;113(1):154-64
pubmed: 18840713
FEBS Lett. 1998 Jul 17;431(2):268-72
pubmed: 9708917
Mol Oncol. 2015 Aug;9(7):1406-20
pubmed: 25933687
Oncogene. 2009 Aug;28 Suppl 1:S14-23
pubmed: 19680292
Chin J Cancer. 2011 May;30(5):287-92
pubmed: 21527061
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
Cancer Metastasis Rev. 2017 Sep;36(3):463-473
pubmed: 28866730
Clin Cancer Res. 2017 May 1;23(9):2143-2153
pubmed: 28143872
Front Oncol. 2016 May 04;6:112
pubmed: 27200298
Int J Radiat Biol. 2011 Nov;87(11):1135-46
pubmed: 21913819
Cell Chem Biol. 2018 Jan 18;25(1):67-77.e3
pubmed: 29129716
Cell Stem Cell. 2019 Jan 3;24(1):153-165.e7
pubmed: 30472158
Annu Rev Cell Dev Biol. 2015;31:249-67
pubmed: 26566113
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Res. 2010 Sep 1;70(17):6704-14
pubmed: 20643779
Trends Cancer. 2017 May;3(5):347-356
pubmed: 28718412
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Ther Adv Med Oncol. 2014 Sep;6(5):240-53
pubmed: 25342991
Hematol Oncol Clin North Am. 2017 Feb;31(1):83-99
pubmed: 27912836
Drugs. 2018 Dec;78(18):1947-1953
pubmed: 30506139
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
Nat Commun. 2015 Mar 16;6:6517
pubmed: 25774828
J Thorac Oncol. 2016 Apr;11(4):556-65
pubmed: 26724471
J Cell Biol. 2008 May 19;181(4):639-53
pubmed: 18490513
Cancer Chemother Pharmacol. 2010 Jul;66(2):381-8
pubmed: 19921194
Nat Rev Clin Oncol. 2010 Sep;7(9):493-507
pubmed: 20551942
J Clin Invest. 2007 Aug;117(8):2051-8
pubmed: 17671639
Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6955-60
pubmed: 27274057
Front Mol Biosci. 2017 Sep 29;4:67
pubmed: 29034245
Respir Res. 2019 Jul 22;20(1):164
pubmed: 31331328
Mol Cell Biol. 2015 Sep;35(18):3131-44
pubmed: 26124282
Cancer Res. 2007 Mar 1;67(5):2046-53
pubmed: 17332333
Mol Cancer Ther. 2006 Oct;5(10):2512-21
pubmed: 17041095
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13092-7
pubmed: 17670948
Oncotarget. 2010 Nov;1(7):497-514
pubmed: 21165163
Nucleic Acids Res. 2016 May 5;44(8):3788-800
pubmed: 27034466
J Clin Oncol. 2003 Oct 15;21(20):3798-807
pubmed: 12953099
Cancer Res. 2013 Oct 15;73(20):6289-98
pubmed: 23980093
J Clin Invest. 2006 Oct;116(10):2695-706
pubmed: 16906227

Auteurs

Petr Makhov (P)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Igor Bychkov (I)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Department of Medical Biophysics, N. I. Pirogov Russian National Research Medical University, Ostrovitianov Street 1, Moscow, 117997, Russia.
Division of Hematology/Oncology, Section of Thoracic Head and Neck Medical Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.

Bulat Faezov (B)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, ul. Karl Marx 18, Kazan, 420012, Russia.

Alexander Deneka (A)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, ul. Karl Marx 18, Kazan, 420012, Russia.

Alexander Kudinov (A)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Department of Internal Medicine, University of New Mexico School of Medicine, 2425 Camino de Salud, Albuquerque, NM, 87106, USA.

Emmanuelle Nicolas (E)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Rohan Brebion (R)

Temple University School of Medicine, 3500N. Broad St, Philadelphia, PA, 19140, USA.

Eleanor Avril (E)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Kathy Q Cai (KQ)

Histopathology Facility, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Leonid V Kharin (LV)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
National Medical research center for Oncology, 63, 14th Liniya, Rostov-on-Don, 344019, Russia.

Mark Voloshin (M)

Rostov State Medical University, 29, Nakhichevanskii pr, Rostov-on-Don, 344022, Russia.

Elena Frantsiyants (E)

National Medical research center for Oncology, 63, 14th Liniya, Rostov-on-Don, 344019, Russia.

Nikolay Karnaukhov (N)

National Medical research center for Oncology, 63, 14th Liniya, Rostov-on-Don, 344019, Russia.

Oleg I Kit (OI)

National Medical research center for Oncology, 63, 14th Liniya, Rostov-on-Don, 344019, Russia.

Iuliia Topchu (I)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, ul. Karl Marx 18, Kazan, 420012, Russia.
Division of Hematology/Oncology, Section of Thoracic Head and Neck Medical Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.

Rushaniya Fazliyeva (R)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Anna S Nikonova (AS)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Ilya G Serebriiskii (IG)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, ul. Karl Marx 18, Kazan, 420012, Russia.

Hossein Borghaei (H)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Martin Edelman (M)

Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Essel Dulaimi (E)

Department of Pathology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Erica A Golemis (EA)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

Yanis Boumber (Y)

Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA. yanis.boumber@northwestern.edu.
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, ul. Karl Marx 18, Kazan, 420012, Russia. yanis.boumber@northwestern.edu.
Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA. yanis.boumber@northwestern.edu.
Division of Hematology/Oncology, Section of Thoracic Head and Neck Medical Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. yanis.boumber@northwestern.edu.

Classifications MeSH